West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical Services, Inc. (NYSE: WST ) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08. Net sales of $872.3 million increased 13.8% year over year, with organic growth of 12.7%, beating the consensus of $838.586 million. HVP Products And GLP-1 Demand Drive Growth Proprietary Products sales of $722.6 million grew by 16.6% and increased 15.5% on an organic basis. High-Value Product (HVP) Components net sales of $424.1 million increased 19.4% and rose 18.4% on an organic basis. During the earnings call, CEO Eric Green said, “This was driven by our three growth drivers, which include biologics and biosimilars, HVP upgrades including Annex 1, and continued strength in GLP-1 elastomers. We continue to believe in the near- and long-term growth prospects of...
West Pharmaceutical Services, Inc. (NYSE: WST ) reported better than expected second quarter 2026 earnings. 08. 586 million.
5% on an organic basis. 4% on an organic basis. During the earnings call, CEO Eric Green said, “This was driven by our three growth drivers, which include biologics and biosimilars, HVP upgrades including Annex 1, and continued strength in GLP-1 elastomers. 2%).
7%). 8%), slightly below expectations due to the impact of the cyber incident. Read Also: Investors Await Damage Assessment After West Pharmaceutical Cyberattack West Raises 2026 Guidance “As a result of our team’s strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance,” commented Eric Green. 61.
332 billion. 12. 71 million. Broader HVP Growth Despite Cost Pressures CFO Robert (Bob) McMahon said increased guidance is driven by higher growth expectations for the non-GLP-1 portion of HVP components as well as an increase in HVP delivery devices.
The company anticipates both GLP-1 and non-GLP-1 HVP components are now expected to grow in the high teens for the year. From a margin perspective, West Pharma is experiencing some inflationary pressure from higher oil and commodity prices, and it is working to offset those costs. 01 at the time of publication on Thursday, according to Pro data. 15 Trillion Defense Package Image Via Shutterstock